Science Corp just closed a $230M Series C at a $1.5B valuation, bringing total funding to $489M to c...
The AMW Read
The funding updates a key player in the BCI/neurotech space and reinforces the high capital intensity of the vertical healthcare/bio-interface sub-segment, though it falls below the cross.§D threshold.
Science Corp just closed a $230M Series C at a $1.5B valuation, bringing total funding to $489M to commercialize its PRIMA brain-computer interface retinal implant. The Neuralink rival, founded by Max Hodak, demonstrated the first BCI technology to restore functional vision and reading ability in patients blinded by macular degeneration, with results published in the New England Journal of Medicine. This funding validates the therapeutic BCI market and positions Science to potentially become the first company to bring a brain interface product to market, aided by its strategic in-house MEMS manufacturing capability. With over $1.3B flowing into neurotech in 2025 alone, the race to commercialize brain-computer interfaces is intensifying across vision restoration, paralysis treatment, and cognitive enhancement applications.
